Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
uMRD profiling determines mutations connected with urothelial carcinoma through next-generation sequencing.
Patients received weekly doses of docetaxel 80 mg, gemcitabine 1000 mg or 2000 mg, and biweekly cisplatin 100 mg.
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
The guidelines included recommendations for treatment with TURBT and postoperative intravesical chemotherapy.
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
The trial indicated a "favorable risk/benefit ratio and quality of life" associated with the treatment.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Nadofaragene firadenovec-vncg is now fully available for health care providers to prescribe across the US for NMIBC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.